Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams

Laura M. Spring, MD, a breast cancer medical oncologist, and Sunil Badve, MD, FRCPath, a surgical pathologist, provide insights into the role and utility of Ki-67 testing in HR-positive/HER2-negative early breast cancer in this expert commentary.

Sunil Badve, MD, FRCPath Laura M. Spring, MD Released: September 26, 2022

Are you testing for Ki67 expression levels in patients with early-stage hormone receptor-positive/HER2-negative breast cancer? Read this commentary for a pathologist’s perspective on Ki67 testing.

Sunil Badve, MD, FRCPath Released: December 28, 2021

Download this slideset from a live workshop series to gain more insight into the optimal utilization of Ki67 testing in HR-positive/HER2-negative early breast cancer, including a review of the latest evidence and practical clinical insights from expert faculty.

Joyce O'Shaughnessy, MD
Program Director Sara Tolaney, MD, MPH
Program Director Released: March 4, 2022

In this on-demand webcast from a live webinar, Joyce O’Shaughnessy, MD, reviews the current data supporting the utilization of Ki67 testing in HR-positive/HER2-negative early breast cancer, including strategies to promote adherence to oral CDK4/6 inhibitors.

Joyce O'Shaughnessy, MD
Program Director Sara Tolaney, MD, MPH
Program Director Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 11, 2022 Expired: No longer available for credit